Approved September 1996
open-angle glaucoma and ocular hypertension
Alphagan has been approved for the treatment of open-angle glaucoma and ocular hypertension.
Alphagan is a selective alpha-2 agonist, which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world.
The Alphagan (brimonidine) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.